| Primary |
| Hiv Infection |
15.3% |
| Product Used For Unknown Indication |
8.2% |
| Adenovirus Infection |
7.7% |
| Prophylaxis |
7.7% |
| Fluid Replacement |
5.6% |
| Sedation |
5.6% |
| Prophylaxis Against Graft Versus Host Disease |
5.1% |
| Atypical Mycobacterial Infection |
4.6% |
| Cytomegalovirus Infection |
4.6% |
| Herpes Simplex |
4.6% |
| Progressive Multifocal Leukoencephalopathy |
4.6% |
| Bk Virus Infection |
4.1% |
| Infection |
4.1% |
| Respiratory Papilloma |
3.1% |
| Antibiotic Prophylaxis |
2.6% |
| Cytomegalovirus Chorioretinitis |
2.6% |
| Infection Prophylaxis |
2.6% |
| Ureteral Stent Insertion |
2.6% |
| Ureteral Stent Removal |
2.6% |
| Vomiting |
2.6% |
|
| Drug Ineffective For Unapproved Indication |
23.0% |
| Renal Failure |
8.2% |
| Nephropathy Toxic |
6.6% |
| Renal Impairment |
6.6% |
| Renal Tubular Disorder |
6.6% |
| Respiratory Failure |
4.9% |
| Drug Ineffective |
3.3% |
| Drug Resistance |
3.3% |
| Neurodegenerative Disorder |
3.3% |
| Progressive Multifocal Leukoencephalopathy |
3.3% |
| Pulmonary Hypertension |
3.3% |
| Pyrexia |
3.3% |
| Renal Failure Acute |
3.3% |
| Respiratory Depression |
3.3% |
| Squamous Cell Carcinoma |
3.3% |
| Uveitis |
3.3% |
| Vomiting |
3.3% |
| Vulvitis |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
| Agranulocytosis |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
17.2% |
| Hiv Infection |
13.9% |
| Septic Shock |
8.2% |
| Bone Marrow Conditioning Regimen |
6.6% |
| Cystitis Haemorrhagic |
5.7% |
| Viral Haemorrhagic Cystitis |
5.7% |
| Adenovirus Infection |
4.1% |
| Antibiotic Prophylaxis |
4.1% |
| Castleman's Disease |
4.1% |
| Graft Versus Host Disease |
4.1% |
| Bk Virus Infection |
3.3% |
| Bone Marrow Transplant |
3.3% |
| Premedication |
3.3% |
| Progressive Multifocal Leukoencephalopathy |
3.3% |
| Skin Papilloma |
3.3% |
| Cytomegalovirus Infection |
2.5% |
| Infection Prophylaxis |
2.5% |
| Acute Myeloid Leukaemia |
1.6% |
| Anaemia Haemolytic Autoimmune |
1.6% |
| Gastritis |
1.6% |
|
| Renal Failure Acute |
17.5% |
| Drug Ineffective For Unapproved Indication |
15.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
12.5% |
| Septic Shock |
12.5% |
| Myelodysplastic Syndrome |
5.0% |
| Progressive Multifocal Leukoencephalopathy |
5.0% |
| Encephalitis Viral |
2.5% |
| Ill-defined Disorder |
2.5% |
| Nephropathy Toxic |
2.5% |
| Pulmonary Hypertension |
2.5% |
| Pyrexia |
2.5% |
| Red Blood Cell Count Decreased |
2.5% |
| Renal Failure |
2.5% |
| Renal Impairment |
2.5% |
| Renal Tubular Disorder |
2.5% |
| Respiratory Failure |
2.5% |
| Unevaluable Event |
2.5% |
| Vomiting |
2.5% |
| White Blood Cell Count Decreased |
2.5% |
|
| Concomitant |
| Hiv Infection |
27.7% |
| Diarrhoea |
11.3% |
| Product Used For Unknown Indication |
10.2% |
| Cytomegalovirus Infection |
9.1% |
| Herpes Simplex |
7.3% |
| Depression |
4.4% |
| Insomnia |
4.0% |
| Antiviral Prophylaxis |
3.6% |
| Cachexia |
3.6% |
| Weight Increased |
3.6% |
| Bone Marrow Transplant |
2.2% |
| Pain |
2.2% |
| Dizziness |
1.8% |
| Infection |
1.8% |
| Acute Leukaemia |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Nausea |
1.5% |
| Anaemia |
1.1% |
| Blood Calcium Decreased |
0.7% |
| Keratitis |
0.7% |
|
| Osteonecrosis |
22.6% |
| Mycobacterium Avium Complex Immune Restoration Disease |
19.4% |
| Cytomegalovirus Infection |
6.5% |
| Immune Reconstitution Syndrome |
6.5% |
| Jaundice |
6.5% |
| Mycobacterium Avium Complex Infection |
6.5% |
| Skin Toxicity |
6.5% |
| Weight Decreased |
6.5% |
| Decreased Appetite |
3.2% |
| Drug Ineffective |
3.2% |
| Hepatic Failure |
3.2% |
| Parkinsonism |
3.2% |
| Renal Failure Acute |
3.2% |
| Toxic Epidermal Necrolysis |
3.2% |
|
